[1] Lane NE, Brandt K, Hawker G, et al.OARSI-FDA initiative: defining the disease state of osteoarthritis.Osteoarthritis Cartilage.2011;19 (5):478-482.[2] Bijlsma JW, Berenbaum F, Lafeber FP. Lafeber Osteoarthritis: an update with relevance for clinical practice.Lancet.2011; 377(9783):2115-2126.[3] Pereira D, Peleteiro B, Araújo J, et al.Ramos The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review .Osteoarthritis Cartilage. 2011;19 (11):1270-1285.[4] Altman RD.Criteria for classification of clinical osteoarthritis.J Rheumatol Suppl.1991;27:10-12.[5] 卫法泉.骨性关节炎诊治(讨论指南)[A]. 浙江省医学会疼痛学分会成立大会暨首届浙江省医学会疼痛学分会学术年会论文汇编[C]. 2011 [6] Berenbaum F. Osteoarthritis year 2010 in review: pharmacological therapies.Osteoarthritis Cartilage.2011;19: 361-365.[7] Hawker GA,Mian S,Bednis K,et al.Osteoarthritis year 2010 in review:non-pharmacologic therapy. Osteoarthritis Cartilage. 2011;19:366-374.[8] Kapoor M, Martel-Pelletier J, Lajeunesse D, et al.Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol.2011;7:33-42.[9] Madry H.The subchondral bone: a new frontier in articular cartilage repair. Knee Surg Sports Traumatol Arthrosc.2010; 18:417-418.[10] Goldring SR.Alterations in periarticular bone and cross talk between subchondral bone and articular cartilage in osteoarthritis. Ther Adv Musculoskelet Dis.2012;4:249-258.[11] De Rezende MU, de Campos GC,Pailo AF. Current concepts in osteoarthritis.Acta Ortop Bras.2013;21(2):120-122.[12] Koepfli JB,Mead JF, Brockm AN JA Jr, An alkaloid with high antimalarial activity from dichroa febrifuga. J Am Chem Soc. 1947;69(7):1837.[13] Ryley JF, Wilson RG. Laboratory studies with some recent anticoccidials. Parasitology.1975;70(2):203-222.[14] ABLONDI F,GORDON S,Morton J,et al. An antimalarial alka-loid from hydrangea.Ⅱ.Isolation. J Org Chem.1952; 17:14 -18.[15] Spector I, Zilberstein Y, Lavy A, et al.Involvement of host stroma cells and tissue fibrosis in pancreatic tumor development in transgenic mice.PLoS One. 2012;7(7): e41833.[16] Leiba M,Cahalon L,Shimoni A,et al.Halofuginone inhibits NF-kappa B and p38 MAPK in activated T cells. J Leukoc Biol.2006;80(2): 399-406.[17] 梁洁,张蓓,刘佳宝,等.常山酮对大鼠肝纤维化的影响及其机制[J].中草药, 2013, 44(23): 3352-3358.[18] Sheffer Y,Leon O, Pinthus J H, et al. Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect. Mol Cancer Ther. 2007;6(2): 570-577.[19] Cui Z, Crane J, Xie H, et al.Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone. Ann Rheum Dis. 2016;75(9): 1714-21[20] 叶常青.形态计量学在病理学中应用的回顾与展望.中华病理学杂志, 1990;19(4):241.[21] 何仁豪,史晨辉.骨性关节炎发病机制及与 micro RNA相关性研究进展[J].中华实用诊断与治疗杂志,2012,26(11):1045-1047.[22] 翟吉良, 翁习生, 邱贵兴.骨关节炎动物模型的建立及选择[J].中国矫形外科杂志, 2007, 15(11): 843-845.[23] Makin HJ, Dorfman H,Lippiello L,et al.Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg (Am). 1971;53(3): 523-537.[24] Park MK, Park JS, Park EM, et al. Halofuginone ameliorates autoimmune arthritis in mice by regulating the balance between Th17 and Treg cells and inhibiting osteoclastogenesis. Arthritis Rheumatol 2014;66:1195-1207.[25] Harrington LE, Hatton RD, Mangan PR, et al.Interleukin 17-producing CD4 + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123-1132.[26] Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol.2005;6:1133-1141.[27] Mattey DL, Dawes PT, Nixon NB, et al. Transforming growth factor beta 1 and interleukin 4 induced alpha smooth muscle actin expression and myofibroblast-like differentiation in human synovial fibroblasts in vitro: modulation by basic fibroblast growth factor.Ann Rheum Dis.1997;56:426-431.[28] Arai Y, Kubo T, Kobayashi K, et al. Adenovirus vector-mediated gene transduction to chondrocytes : in vitro evaluation of therapeutic efficacy of transforming growth factor -beta 1 and heat shock protein 70 gene transduction. Rheumatol.1997;24( 9):1787-1795.[29] Fang PK, Ma XC, Ma DL, et al. Determination of interleukin-1 receptor antagonist, interleukin-10, and transforming growth factor-beta1 in synovial fluid aspirates of patients with temporomandibular disorders.Oral Maxillofac Surg.1999; 57(8): 922-8; discussion 928-929.[30] 陈百成,张洪斌,张汉杰,等.生长因子对软骨细胞的作用[J].中华骨科杂志,1999,19(12):746-748. |